- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00186459
Obesity, Weight Loss, and Cardiovascular Disease Risk
GCRC-CAP-Tracey McLaughlin, MD
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
While obesity, insulin resistance, and diabetes are highly associated, it is not clear whether insulin resistance and compensatory hyperinsulinemia play important roles in the tendency to gain weight and/or inability to lose weight. The role of hyperinsulinemia in coronary heart disease (CHD)is also unclear. The specific aims of the proposed research are as follows:
- To compare insulin resistant versus insulin sensitive nondiabetic overweight individuals with respect to their ability to lose weight on a low calorie diet. CHD risk factors before and after weight loss will also be assessed to determine the degree to which insulin resistance is associated with CHD risk, as well as the impact that differences in insulin resistance have on the metabolic benefits of weight loss
- To determine if weight loss and its associated metabolic benefits vary as a function of the relative amounts of dietary fat and carbohydrate in hypocaloric diets. Because high carbohydrate diets increase insulin secretion, the relationship between dietary composition and change in circulating insulin concentrations will be analyzed with respect to both weight loss and CHD risk factors.
- To quantify and compare the improvement in glycemic control and CHD risk factors associated with weight loss in obese type 2 diabetics, while being treated with 1) an insulin secretagogue (sulfonylurea) or 2) an insulin sensitizer (thiazolidinedione). Manipulation of plasma insulin concentrations with these medications will provide a mechanism by which to evaluate the impact of circulating insulin concentrations on the described outcome measures.
- A subgroup of overweight/obese premenopausal women with PCOS will be studied using two diets in crossover design with regard to macronutrient effects on endogenous hyperinsulinism. For this subgroup age range will be 18-50 years, BMI 25-50 kg/m2.
- In order to increase our data and therefore increase our better understanding of fat cells and insulin resistance and changes in fat cells with weight loss we would like to increase our participant enrollment to 550 all to be enrolled at Stanford University Medical Center recruiting Bariatric participants:
Age for Bariatric patients 30-65 men and women BMI 27-no upper limit Currently we have completed all participants except the bariatric and post bariatric population and those with hypoglycemia following bariatric surgery.
The ethnic background of subjects reflects Stanford's patient population.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Stanford University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- BMI 30-35
- age 35-65
- nondiabetic by fasting plasma glucose concentration
- no active major organ diseases
- insulin resistant or insulin sensitive
Exclusion Criteria:
- anemia
- pregnant
- major organ disease
- active malignancy
- eating disorder
- active psychiatric illness
- chronic inflammatory conditions
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Weight loss
|
Secondary Outcome Measures
Outcome Measure |
---|
Lipid/lipoprotein changes
|
Blood pressure changes
|
Insulin resistance changes
|
Endothelial function changes
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Dr Tracey Lynn McLaughlin, Stanford University
Publications and helpful links
General Publications
- McLaughlin T, Abbasi F, Lamendola C, Yee G, Carter S, Cushman SW. Dietary weight loss in insulin-resistant non-obese humans: Metabolic benefits and relationship to adipose cell size. Nutr Metab Cardiovasc Dis. 2019 Jan;29(1):62-68. doi: 10.1016/j.numecd.2018.09.014. Epub 2018 Oct 11.
- Perelman D, Coghlan N, Lamendola C, Carter S, Abbasi F, McLaughlin T. Substituting poly- and mono-unsaturated fat for dietary carbohydrate reduces hyperinsulinemia in women with polycystic ovary syndrome. Gynecol Endocrinol. 2017 Apr;33(4):324-327. doi: 10.1080/09513590.2016.1259407. Epub 2016 Dec 2.
Study record dates
Study Major Dates
Study Start
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RR16071-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuNot yet recruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on Hypocaloric diet of varying macronutrient composition
-
University of TorontoCanadian Institutes of Health Research (CIHR)CompletedObesity | Cardiovascular Disease | Type 2 Diabetes MellitusCanada
-
Norwegian University of Science and TechnologySt. Olavs Hospital; FUGE Mid-NorwayCompletedCardiovascular Diseases | Obesity | Diabetes MellitusNorway
-
Wake Forest University Health SciencesNational Institute on Aging (NIA); Takeda Pharmaceuticals North America, Inc.CompletedObesity | Overweight With Indications for Weight LossUnited States
-
University of Missouri-ColumbiaCompletedDiabetes Mellitus, Type 2 | HyperuricemiaUnited States
-
SanofiCompletedMetabolic SyndromeUnited States, France, Canada, Spain, United Kingdom, Finland, Italy, Denmark, Sweden
-
Indonesia UniversityDr Cipto Mangunkusumo General Hospital; SEAMEO Regional Centre for Food and...CompletedObesity | Ghrelin | Appetite | Gut Hormones | PYY | VAS of Satiety | VAS of Hunger | GLP - 1Indonesia
-
University Magna GraeciaCompletedPolycystic Ovary Syndrome | AnovulationItaly
-
Vanderbilt University Medical CenterAmerican Heart AssociationCompleted
-
Instituto Mexicano del Seguro SocialRodolfo Guardado Mendoza; Marco Antonio Ocampo Apolonio; Texar Alfonso Pereyra...CompletedCoronary CalcificationMexico
-
Istituto Auxologico ItalianoUniversità Politecnica delle Marche; University of MilanCompleted